With immunochemotherapy, remission duration and survival in patients with chronic lymphocytic leukaemia is dependent on the level of minimal residual disease (MRD) after treatment. This phase II trial assessed alemtuzumab consolidation post-chemotherapy in patients who responded with persistent low levels of detectable disease. Blood was screened for MRD using multi-parameter flow cytometry, 6-24 months post-chemotherapy. MRD-positive participants received alemtuzumab 30 mg subcutaneously 3 times weekly for 6 weeks. Following a marrow assessment, MRD-negative participants or non-responders stopped therapy and MRD-positive participants with 1 + log reduction had 6 more weeks of alemtuzumab. Alemtuzumab consolidation was received by 47 participants. One death and 19 of 22 serious adverse events reported from 17 (36%) participants were alemtuzumab-related. MRD eradication from blood and bone marrow was achieved in 39 (83%) participants at the end of consolidation, with 18 (38%) remaining MRD-negative in the blood 6 months later. Of the 18 participants who were MRD-negative at 6 months, the median time to MRD relapse was 46 months, which was similar to patients who were MRD-negative at baseline and were followed up. The 5-year progressionfree survival (PFS) and overall survival (OS) of participants who were MRD-negative at 6 months was significantly better than MRD-positive participants [PFS: 78% vs. 39% (P = 0Á010), OS: 89% vs. 64% (P = 0Á029)].
Summary
With immunochemotherapy, remission duration and survival in patients with chronic lymphocytic leukaemia is dependent on the level of minimal residual disease (MRD) after treatment. This phase II trial assessed alemtuzumab consolidation post-chemotherapy in patients who responded with persistent low levels of detectable disease. Blood was screened for MRD using multi-parameter flow cytometry, 6-24 months post-chemotherapy. MRD-positive participants received alemtuzumab 30 mg subcutaneously 3 times weekly for 6 weeks. Following a marrow assessment, MRD-negative participants or non-responders stopped therapy and MRD-positive participants with 1 + log reduction had 6 more weeks of alemtuzumab. Alemtuzumab consolidation was received by 47 participants. One death and 19 of 22 serious adverse events reported from 17 (36%) participants were alemtuzumab-related. MRD eradication from blood and bone marrow was achieved in 39 (83%) participants at the end of consolidation, with 18 (38%) remaining MRD-negative in the blood 6 months later. Of the 18 participants who were MRD-negative at 6 months, the median time to MRD relapse was 46 months, which was similar to patients who were MRD-negative at baseline and were followed up. The 5-year progressionfree survival (PFS) and overall survival (OS) of participants who were MRD-negative at 6 months was significantly better than MRD-positive participants [PFS: 78% vs. 39% (P = 0Á010), OS: 89% vs. 64% (P = 0Á029)].
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The treatment of chronic lymphocytic leukaemia (CLL) has seen several advances over the past decade, including the advent of combination immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) as the standard first line treatment and development of new agents, such as several monoclonal antibodies, B-cell receptor signalling pathway inhibitors and BCL2 inhibitors. It is well established that, with immunochemotherapy, patients attaining complete remission (CR) have a better survival rate than those attaining partial response (PR) or less. This led to the concept of improving the depth of response up to the point of eradication of minimal residual disease (MRD), which is a standard practice in many other haematological malignancies (Hallek et al, 2008) . In CLL patients treated with different immunochemotherapies, Kwok et al (2009) showed that attainment of MRD-negativity is an independent predictor of overall survival (OS) and progression-free survival (PFS) in a retrospective analysis. In addition MRD-negativity following front-line FCR is a strong predictor of PFS and OS (B€ ottcher et al, 2012) , (Strati et al, 2014) .
At the time of trial recruitment, alemtuzumab, a humanised monoclonal antibody specific for CD52, was licensed for the treatment of refractory CLL. But, from 2012 onwards, alemtuzumab has been available for this purpose only on patient access programmes, as the manufacturer withdrew it due to non-medical reasons. However the trial still serves as a proof of principle for consolidation treatment, and there are several other effective monoclonal antibodies that can be used for further trials. Previous trials consistently showed that alemtuzumab is more efficacious when administered to patients with lower levels of disease (Osterborg et al, 1997; Keating et al, 2002; Lundin et al, 2002) , providing a rationale to use the drug as consolidation when patients have only MRD detectable after chemoimmunotherapy and no bulk disease. The German CLL4B trial, a phase III trial to compare alemtuzumab consolidation against observation after purine analogue therapy, was prematurely stopped due to infectionrelated toxicity (Wendtner et al, 2004) , (Schweighofer et al, 2009) . A long-term follow-up of the 21 participants has shown that PFS was significantly prolonged for the 11 treated participants versus those in observation arm (Schweighofer et al, 2009) . Possible reasons for the toxicity were the proximity to initial therapy, dose and route of administration. In treatment for clinically progressive disease, the median duration of alemtuzumab therapy required to attain an MRD-negative CR was 9 weeks in a study of 91 participants (Moreton et al, 2005) . The pharmacokinetics of alemtuzumab in MRD is more likely to be related to that observed in the bone marrow transplant setting than with conventional CLL treatment due to the low level of disease (Hale et al, 2004) , (Rebello et al, 2001 ). Thus, for MRD level treatment, a reasonable dosing strategy was selected to be 30 mg three times weekly subcutaneously for 6 weeks, at least 6 months after the last chemotherapy, with the treatment period extended to 12 weeks if necessary. Moreover, careful surveillance for infection and pre-emptive treatment, if needed, would help to reduce the infection-related toxicity in these patients.
Methods

Trial design
CLL207 was a phase II, multi-centre, single-arm study to determine the efficacy and safety of alemtuzumab consolidation in patients with low levels of MRD, defined as >1 CLL cell in 10 000 leucocytes, following conventional therapy. The joint primary endpoints were the MRD-negativity rate at the end of therapy and the proportion of participants experiencing a predefined unacceptable level of toxicity. The secondary objectives were to assess clinical response to alemtuzumab therapy as defined by National Cancer Institutes (NCI) Criteria (Cheson et al, 1996) , time to MRD relapse, PFS, OS and the pharmacokinetic profile of alemtuzumab in the MRD setting. An unacceptable toxicity was defined as any death or toxicity of grade 3 or above attributed to the study treatment or its complications, excluding lymphopenia, grade 3 neutropenia or grade 4 neutropenia responding to granulocyte colony-stimulating factor (G-CSF). A two-stage design was planned to incorporate a stopping rule if the treatment was not felt to be acceptable in terms of either efficacy or toxicity. The sample size was determined using the Bryant and Day design which incorporates toxicity considerations as well as clinical responses (Bryant & Day, 1995) . The calculation was based on the assumptions that an MRD rate over 40% and toxicity rate under 20% is desired, and an MRD rate below 20% and toxicity rate above 40% is unacceptable. With 10% significance and 90% power, a total of 54 participants were planned, with the stage I assessment after 24 participants. An independent Data Monitoring and Ethics Committee (DMEC) reviewed the safety and ethics of the study. The trial was approved by all relevant institutional ethical committees and regulatory review bodies, and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.
Patients
Eligible patients had completed chemotherapy for CLL between 6 and 24 months prior to registering, having attained a complete or partial remission. They did not have lymph nodes greater than 2 cm in diameter by computed tomography scan nor a peripheral B-cell count more than 5 9 10 9 /l, and had not received more than 3 prior therapies for CLL or an allogeneic transplant. Patients who previously failed alemtuzumab therapy and those with persisting severe pancytopenia due to previous therapy rather than disease were also excluded. MRD status was assessed at entry; MRDpositive participants received consolidation therapy in the Main Study; MRD-negative participants were followed up within the study and only treated if they become MRD-positive during the eligibility period, otherwise they were followed under a Monitoring Investigation.
Treatment
Participants were treated with 30 mg subcutaneous alemtuzumab three-times weekly for 6 weeks after which bone marrow and peripheral blood were assessed for MRD. Alemtuzumab was stopped if the bone marrow was MRD-negative or if there was no significant improvement in the level of CLL cells. Participants who were responding but remained MRD-positive were treated with a further 6 weeks of alemtuzumab and then reassessed for MRD. Peripheral blood MRD status was reassessed every 3 months after treatment. Participants were eligible to be retreated with alemtuzumab when they become MRD-positive, if they had remained MRD-negative for at least 6 months (Fig 1) . Standard antimicrobial prophylaxis for alemtuzumab was given, including monitoring of cytomegalovirus (CMV) by polymerase chain reaction (PCR). Participants with neutrophils below 1Á0 9 10 9 /l were treated with G-CSF (filgrastim 300 lg three-times weekly on the days of alemtuzumab treatment).
Treatment was interrupted in the presence of the following events: platelet count <25 9 10 9 /l or neutrophil count <0Á25 9 10 9 /l, grade 4 non-haematological toxicity, and grades 3-4 infection. Following the recovery of the platelet count to >50 9 10 9 /l and neutrophil count to >0Á5 9 10 9 /l, alemtuzumab was re-introduced.
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Response assessments
MRD response assessments were based on the bone marrow MRD findings, and were categorised as follows:
MRD-negative response. No detectable CLL in the bone marrow and peripheral blood by 4-colour flow cytometry and absence of lymphadenopathy and organomegaly attributed to CLL (Rawstron et al, 2007) .
Partial response. At least 1 logarithmic (log) reduction in bone marrow CLL cells but still MRD-positive.
Progressive disease. At least 1 log increase in bone marrow CLL cells or new clinically evident lymphadenopathy or splenomegaly.
Stable disease. Not falling into any of the above categories. Clinical response was also assessed according to the NCI response criteria 1996 (Cheson et al, 1996) .
Pharmacokinetics study
A pharmacokinetics study was planned on consenting participants from selected centres. Serum alemtuzumab concentration was analysed using indirect immunofluorescence, as described by Hale et al (2004) at baseline, 3, 6, 9 and 12 weeks of treatment, where appropriate, and at 1, 2, 4, 6 and 12 weeks after treatment.
Statistical methods
Response rates derived based on bone marrow findings as well as NCI criteria are summarised for the Main Study population and 95% confidence intervals (CI) reported for the proportion of participants who became MRD-negative. Time to MRD relapse, PFS and OS are described using Kaplan-Meier curves. Safety is summarised by the number and proportion of participants who suffer an unacceptable toxicity, and 95% CI reported. Details of the toxicities are also summarised using adverse event (AE) and treatment-related mortality rates. Planned subgroup analyses summarise the primary endpoints, MRD relapse and survival data (where appropriate).
Results
Participant characteristics
Sixty-one participants with written informed consent were registered between December 2006 and January 2010 from 11 UK institutions with local ethical and management approval. Forty-seven participants were treated within the Main Study, of which 43 had detectable disease at registration and 4 became MRD-positive within 24 months of completing their prior therapy. 11 participants remained in the Monitoring Investigation and 3 withdrew or were found to be ineligible before receiving treatment. The CONSORT diagram (Schulz et al, 2010) (Fig 2) shows the flow of participants throughout the trial. The recruitment target of 54 participants to the Main Study was not met due to slower than anticipated recruitment. Baseline characteristics of the participants in the Main Study are displayed in Table I . The median age was 58 years (range 40-77) with 75% males. The relatively young population is expected given the concerns of additional toxicity with alemtuzumab. 49% had received just one prior therapy, and 30% had received two (range 1-4). 98% received prior fludarabine and 19% prior rituximab. 45% had responded to prior therapy with a CR and 55% with a PR. The mean neutrophil count of the participants was 2Á91 9 10 9 /l (range 0Á7-5Á1), lymphocyte count was 1Á45 9 10 9 /l (range 0Á3-6Á2), 49% had a normal or high IgG level and 28% had a low but detectable IgG.
Treatment
The duration of treatment received is summarised in Table II . Of the 47 participants, 6 (12Á8%) did not receive the full 6 cycles as protocolled. Twelve (25Á5%) participants were eligible to be treated for a further 6 weeks, and 4 (33Á3%) of these did not receive all 12 cycles. Reasons for early stopping included AEs, CMV reactivation, cytopenia and participant choice. Twenty (42Á6%) participants had a dose delay or modification for at least 1 week of treatment.
Primary endpoint analysis
At the analysis of stage I, reported to the DMEC in December 2008, 18/24(75Á0%) participants had responded to treatment with MRD-negativity, and 5(20Á8%) had suffered an unacceptable adverse reaction (AR), which did not pass the planned stopping boundaries. The DMEC felt that the toxicity was significant but manageable, and as the efficacy outcome was encouraging, the trial should proceed.
At the stage II analysis, summarised in Table II , 39/47 (83%; 95%CI: 69-92%) responded to treatment with MRDnegativity, which greatly exceeded the stopping boundary for efficacy of 13 responses. The denominator includes the participant with a missing response, to ensure the most conservative response rate by intention to treat. An unacceptable AR occurred in 10/47(21Á3%), which was less than the stopping boundary of 15 participants, so the pre-defined stopping criteria were not met.
Efficacy endpoints
The overall response rate (ORR), defined as complete or partial remission (CR/PR) by NCI Criteria, was 91Á5% as summarised in Table II . As of August 2015, the median follow-up for survivors was 6Á3 years. The 5-year PFS and OS was 53Á2%, and 72Á2%, respectively. Kaplan-Meier OS and PFS curves are presented in Figs 3A , B respectively. The median time to progression was 70 months, and the median OS was not yet reached. Of the 39 participants who became MRD-negative following treatment, the 5-year survival for MRD relapse, progression or death was 11Á2%. The median duration of MRD-negativity was 6Á7 months (95%CI: 5Á6, 25Á0). 21/39 MRD-negative participants (53Á8%) became MRD-positive within 6 months of completing therapy, and participants who remained MRD-negative beyond 6 months appeared to have a greater chance of sustained MRD-negativity, as illustrated by the Kaplan-Meier MRD curve (Fig 3C) . If MRDnegativity is assessed in the peripheral blood 6 months after completing alemtuzumab, 18/47 participants (38%) reached this target (Table II) . PFS and OS were significantly better in the MRD-negative participants at 6 months compared to those who were MRD-positive (P-values 0Á010 and 0Á029 respectively) ( Figs 4A, B) .
Fifteen participants were MRD-negative at registration to the trial, 4 of whom became MRD-positive and were eligible for trial treatment, and the remaining 11 were followed up for relapse within the monitoring investigation. As of August All values are given as n (%) unless otherwise indicated. *The eligibility criteria were limited to 3 previous lines of therapy after two participants had already entered with 4. 
Subgroup analyses
Nine participants went on to receive 11 or 12 weeks of therapy of which 6(67%) became MRD-negative by the end of treatment, but only 1(11%) remained MRD-negative at 6 months post-alemtuzumab. This suggests that there is no advantage to extend the therapy beyond 6 weeks. Nine participants had previously received rituximab; all became MRD-negative following therapy and 2 (22%) remained MRD-negative after 6 months. None of these participants suffered an unacceptable toxicity.
The MRD responses in participants who had received one [20/23(87%)] or multiple prior therapies [19/24(79%)] were comparable. After 6 months these response rates became 10/ 23(44%) and 8/24(33%) respectively. There was a trend towards more participants who had received multiple prior therapies suffering an unacceptable toxicity [7/24(29%) vs. 3/ 23(13%)], and having a worse median PFS and OS (PFS 71 vs. 45 months; OS not reached vs. 60 months). Given that the subgroup analyses are exploratory, it was not planned to assess significance in the differences between the subgroups, but the trends seen are expected due to the nature of the disease and treatment.
Safety
As of August 2015, 15 participants in the main trial (31Á9%) have died. One death, caused by parainfluenza pneumonitis, was considered directly related to treatment. Two other deaths were the outcome of severe AEs (SAEs), although not directly related to treatment: myelodysplasia-related infection and Epstein-Barr virus (EBV)-driven lymphoproliferative disorder. Other causes of death were: 4 CLL-related infections; 3 overwhelming tumour burden; 2 transformed disease; 1 Crohn's Disease; 1 pulmonary embolism; 1 multiple myeloma. Twenty-two SAEs were reported from 17(36Á2%) participants, with 19 suspected to be related to alemtuzumab, of which 2 were unexpected (serious unexpected serious ARs): the parainfluenza infection resulting in death and an EBV-related diffuse large B-cell lymphoma (DLBCL) leading to upper gastrointestinal haemorrhage. SAEs and AEs are summarised in Table II . Eleven events from 10 participants were considered unacceptable as per protocol definition. Four were considered highly unacceptable: 1 pneumocystis pneumonia;1 parainfluenza-related death and 2 EBV-related transformed diseases. Seven other events were easily manageable but considered unacceptable due to requirement of intravenous antibiotics (n = 5), grade 4 thrombocytopenia (n = 1) and grade 4 neutropenia not responding to G-CSF (n = 1).
A total of 414 AEs were reported with 339 suspected to be alemtuzumab-related, the most common being rash (13%), cytopenia (13%), fatigue (8%), non-specific respiratory symptoms (8%) and fever (5%).Twenty-one (44Á7%) of the treated participants had a positive CMV PCR during alemtuzumab; 19 (90Á5%) occurred within the first 3 weeks of treatment. Thirty participants received growth factor support before treatment (n = 3), while on treatment (n = 12) or after treatment (n = 15). G-CSF support varied widely, from pre-treatment to 27 months post treatment, with a median duration of 11 months (range 0-67 months).
Of the 12 participants receiving more than 6 weeks of treatment, 4 SAEs related to alemtuzumab were reported from 3 (25%) participants. Of these, only 2 were reported after the 6th cycle. Of the 11 events that were deemed unacceptable, only 1 was from 1 participant who received 12 cycles (at cycle 12). The other 10 were within the first 6 cycles. This may imply that most of the toxicity happens within the first 6 weeks of treatment itself.
Pharmacokinetics study
Serum alemtuzumab concentration was analysed in 5 participants. Lympholytic level was reached within 3 weeks (when the first post-dose sample was tested) in all participants, unlike refractory patients treated with alemtuzumab in whom it took an average of 6 weeks to reach a concentration of 1 lg/ml. The mean highest concentration in individual participants was 8Á24 lg/ml (range 2Á70-11Á97 lg/ml), similar to the refractory patient group. The drug was detected in plasma up to 11 weeks after finishing treatment.
Discussion
Alemtuzumab consolidation is efficient, with 83% of participants attaining MRD-negativity at the end of treatment. This high rate of MRD-negativity was not sustained, and 54% of MRD-negative participants relapsed at the MRD level in the peripheral blood by 6 months. At this time the MRD relapse curve flattened, suggesting that the 18 participants who remained MRD-negative in their peripheral blood at 6 months had a sustained MRD-negative response. Although a number of participants relapsed quickly at the MRD level, this did not translate into a fast clinical progression or death. Of the 47 treated participants, the 5-year PFS and OS rates were 53% and 72% respectively.
The faster rate of MRD relapse within the first 6 months after treatment compared to beyond this period is probably explained by the redistribution of malignant cells between compartments. It is well described that alemtuzumab clears the disease in blood and marrow much more effectively than nodal disease. It seems likely that residual disease in lymph nodes redistributes to the blood and marrow within the first 6 months after completing alemtuzumab, suggesting that this is not a true relapse, but a redistribution of resistant disease. The participants who relapse beyond this initial 6-month period represent a true progression.
This study also demonstrates that patients benefiting from alemtuzumab consolidation tend to respond within the first 6 weeks of treatment. In addition, peripheral blood MRD level at 6 months after consolidation is a truer indicator of persistent disease at MRD level than a bone marrow sample at the end of treatment, which would be an unnecessary investigation as it is unlikely to change the future disease management.
Participants who attained MRD-negativity have a better PFS and OS compared to those who remained MRD-positive. Previously, the Cancer and Leukemia Group B (CALGB) 10101 trial, an alemtuzumab consolidation trial, showed no statistically significant difference in 2-year PFS and OS between consolidated and non-consolidated groups (PFS 76 vs. 68% P = 0Á35; OS 84 vs. 88% P = 1Á0), but here the consolidation treatment was given only to participants in PR or with stable disease, but not MRD-positive CRs (Lin et al, 2010) . The German CLL4B trial, however, randomised just 21 participants but showed a significant difference between participants who were consolidated versus not consolidated, with 3-year PFS 81Á8% vs. 30Á0% (P = 0Á004) (Schweighofer et al, 2009) , with participants receiving alemtuzumab having pronounced reductions in MRD levels. Long-term follow-up data from the German CLL8 trial has also shown that low (<10 À4 ) level MRD was associated with significantly better PFS and OS compared to intermediate (≥10 À4 to <10 À2 ) and high (≥10 À2 ) level MRD (B€ ottcher et al, 2012) . Although MRD negativity is not necessary to improve outcomes with certain therapies, such as B-cell receptor inhibitors, achieving MRD negativity is associated with a better outcome in all scenarios that have been studied and as one goal of future therapy is to move to a defined shorter duration of therapy, MRD eradication will be an end-point that can be used to decide when to stop novel therapies, such as ibrutinib or venetoclax. In this setting, as far as we know, the remission will be sustained only if the treatment is continued, but it will be useful to know whether a combination or consolidation with monoclonal antibodies will shorten the duration of therapy. This may have implication both in terms of toxicity of long-term use as well as the cost of treatment. Alemtuzumab is not the right choice in this situation, due to its toxic profile and non-availability for commercial use, but this trial substantiates our understanding that attaining MRD negativity, even with consolidation therapy, can improve the survival outcome in CLL patients. Further analysis showed that the MRD status at the end of treatment is not an accurate determinant of long-term PFS and OS (P = 0Á602 and P = 0Á780 respectively), but the MRD status 6 months after the treatment is. The 5-year PFS and OS of MRD-negative and -positive participants at 6 months are 77Á8% vs. 39Á3% (P = 0Á010) and 88Á9% vs. 63Á9% (P = 0Á029) respectively. Their progression is similar to the participants who were MRD-negative at the entry of trial [HR=1Á57 (95%CI: 0Á62, 3Á97)]. Meaningful interpretations of subgroup analysis for various prognostic factors including genetic factors were not possible due to small numbers in each subgroup.
Alemtuzumab treatment is associated with substantial but manageable toxicity. Delaying the treatment to at least 6 months after the immediate prior treatment meant that patients entering the trial had a relative high proportion of normal haematological and other laboratory parameters. In addition, limiting the duration of treatment to 6 weeks reduces the chance of alemtuzumab being toxic to other CD52 +ve targets, such as CD4 + T-cells. The pharmacokinetic study supports this shorter duration of treatment as the lympholytic dose is reached much earlier, because the disease burden is much smaller when compared to patients with clinical disease. Similarly, patients who had more than one line of previous therapy experienced higher rate of unacceptable toxicity and had shorter PFS and OS. These suggest the need for careful patient selection and possible consideration of consolidation at an earlier stage in the treatment line of CLL. In summary, the CLL207 trial is strongly suggestive that consolidation of MRD-positive to MRD-negative remissions after completing conventional chemotherapy leads to a large improvement in outcome. However, alemtuzumab in this setting carries a significant toxicity and it would be preferable to use a more specific monoclonal antibody that did not deplete T-cells. On the basis of the very promising sustained remissions seen in CLL207 we have commenced a randomised Phase III consolidation trial, the NCRI GALACTIC Trial (ISRCTN64035629), of the anti-CD20 antibody, obinutuzumab, which appears to result in MRD-negative remissions without the immunosuppressive problems associated with alemtuzumab.
